MBX Biosciences to Provide 2026 Outlook and Business Update at 44th Annual J.P. Morgan Healthcare Conference
MBX Biosciences, Inc. (MBX)
Company Research
Source: GlobeNewswire
One-year follow-up data from Phase 2 trial of once-weekly canvuparatide, a potential best-in-class therapy for hypoparathyroidism, anticipated in Q2 2026; Phase 3 initiation on track for Q3 2026 12-week data from Phase 1 trial of MBX 4291, a dual GLP-1/GIP co-agonist prodrug with potential for once-monthly dosing and improved tolerability for obesity, anticipated in Q4 2026 Nomination of two additional obesity candidates expected in 2026: an amycretin prodrug and a GLP-1/GIP/GCGR triple agonist, each designed for once-monthly dosing Strong cash position: preliminary unaudited cash, cash equivalents and marketable securities of approximately $373.7 million as of December 31, 2025, expected to fund operations into 2029 CARMEL, Ind., Jan. 11, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabo
Show less
Read more
Impact Snapshot
Event Time:
MBX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MBX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MBX alerts
High impacting MBX Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
MBX
News
- MBX Biosciences to Provide 2026 Outlook and Business Update at 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- MBX Biosciences (NASDAQ:MBX) was upgraded by analysts at UBS Group AG to a "strong-buy" rating.MarketBeat
- MBX Biosciences (NASDAQ:MBX) is now covered by analysts at UBS Group AG. They set a "buy" rating on the stock.MarketBeat
- MBX Biosciences (NASDAQ:MBX) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=MBX&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen<MarketBeat
- MBX Biosciences (NASDAQ:MBX) was given a new $50.00 price target on by analysts at Stifel Nicolaus. They now have a "buy" rating on the stock.MarketBeat
MBX
Earnings
- 11/6/25 - Beat
MBX
Sec Filings
- 1/12/26 - Form 144
- 1/12/26 - Form 8-K
- 12/9/25 - Form EFFECT
- MBX's page on the SEC website